ADRO
Aduro Biotech Inc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 193.99M; Volume: 80.78K; AvgVol 3m: 475.23K; Beta: 0.39;
Cost estimate:
P/E: –; EPS: -0.80; EPS growth quarter/prev quarter: 11.50%;
EPS growth this year: 15.00%; EPS growth past 5 years: -30.40%;
EPS ttm: -0.80;
P/S: 8.64; P/B: 05.07; P/Cashflow: 1.41; P/FCF: ;
Sales: 27.95M; Sales growth quarter/prev quarter: 14.30%; Sales growth past 5 years: 5.20%;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -22.30%; ROE – return on equity: -101.70%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.70%; Insider Transactions:-36.51%;
Institutional Ownership: 51.40%; Institutional Transactions: 32.97%;
Data update: 07.10.2020.